t(11;14)

MCL Literature Feed

846 papers on mantle cell lymphoma from PubMed. Updated daily.

ADCBCL2iBTKiCAR-TCDK4/6iCNSMRDPI3KiTP53-mutatedbiomarkersbispecificblastoidcase reportchemotherapyconsolidationelderlyepidemiologyfrontlinegenomicsguidelines
An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma.
Toby A Eyre, Leyla Mohseninejad, Lianne Barnieh et al.·Journal of medical economics·Dec 1, 2026
Time to access matters: patient gains from faster CAR T-cell reimbursement in Europe.

Quantifying the survival cost of delayed CAR T-cell reimbursement in Europe shows faster access for MCL patients would translate directly into more lives and life-years saved.

Yan Zhi Tan, Emily Breislin, Matthew Woods et al.·Journal of medical economics·Dec 1, 2026
CAR-Trelapsed/refractoryreal-worldhealth economicsepidemiology
Glofitamab in Heavily Pretreated Mantle Cell Lymphoma Patients: A Multicenter Real-World Case Series.
Natalia Rotter, Markus Raderer, Agnes List et al.·EJHaem·Aug 1, 2026
Inhibition of PRMT5 sensitizes B-cell non-Hodgkin lymphoma cells to both intrinsic and extrinsic apoptotic cell death.
Fen Zhu, Jing Wang, Christine E Ryan et al.·Blood neoplasia·Aug 1, 2026
Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.
Riccardo Moia, Mohammad Almasri, Maria Elena Carazzolo et al.·Blood advances·Jul 24, 2026
Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

Invasive pneumococcal disease unmasks monoclonal immunoglobulins and antibody deficiencies: a multicenter prospective study in adults.
Tor Härnqvist, Karin Bergman, Åsa Mellgren et al.·Scientific reports·Jul 24, 2026
Identifying the angiogenic receptor expression in mantle cell lymphoma patients and murine models.
Satishkumar Singh, Yuanfeng Wang, Anuvrat Sircar et al.·Biomarker research·Jul 24, 2026
The PDPK1-RSK2 axis as a potential convergent therapeutic vulnerability in B-cell lymphomas.
Junya Kuroda, Taku Tsukamoto, Yuji Shimura·Expert opinion on therapeutic targets·Jul 23, 2026
CD70 Overexpression at Diagnosis Predicts Relapse and supports dual CD19-CD70 CAR-T Therapy in Follicular Lymphoma.
Ferran Araujo-Ayala, Maria Ros, Raluca Alexandru et al.·Blood·Jul 22, 2026
Model-Based Analysis with Mechanistic Insights to CAR-T-Cell Therapy Kinetics: Case Study with Axicabtagene Ciloleucel and Brexucabtagene Autoleucel.
Anna M Mc Laughlin, Martin Bergstrand, Ana Ruiz-Garcia et al.·Clinical pharmacology and therapeutics·Jul 21, 2026
Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

Mantle Cell Lymphoma in Geriatric Patients: Biologic Risk Stratification, Fitness-Adapted Strategies, and Unmet Needs.
Victor M Samperio, Moza Hamoud, Ifeoma Ike et al.·European journal of haematology·Jul 21, 2026
Sonrotoclax (Beqalzi) for mantle cell lymphoma.
·The Medical letter on drugs and therapeutics·Jul 20, 2026
Acalabrutinib in patients with mantle cell lymphoma subjected to allogeneic hematopoietic cell transplantation. a phase 2 study by the Polish Lymphoma Research Group (PLRG12 trial).
Sebastian Giebel, Anna Czyż, Iwona Hus et al.·Annals of hematology·Jul 17, 2026
Healthcare resource utilization analysis in newly diagnosed mantle cell lymphoma: resource alleviation with adoption of the TRIANGLE ibrutinib regimen without autologous stem cell transplantation.
Jonas Wißkirchen, Nora S Rogmann, Michael Greiling et al.·Annals of hematology·Jul 16, 2026
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.
Marco Ladetto, Katja Gutmair, Rita Tavarozzi et al.·Journal of clinical oncology : official journal of the American Society of Clinical Oncology·Jul 14, 2026
Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

Erratum: Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.
Toby A Eyre, Yuqin Song, Olivier Hermine et al.·Journal of clinical oncology : official journal of the American Society of Clinical Oncology·Jul 14, 2026
Genetically Predicted Gut Microbiota and Lymphoma Risk: A Mendelian Randomization Study.
Danhua Li, Tongfei Zhou, Meng Liu et al.·Current pharmaceutical biotechnology·Jul 13, 2026
Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study.
Michael Wang, Wojciech Jurczak, Marek Trneny et al.·British journal of haematology·Jul 12, 2026
Expanding the Horizon of CAR-T Cell Therapy: Present Obstacles and New Strategies for Future CARs in Solid Tumors.
Qasim Javed, Shoaib Majeed, Adnan Shahid et al.·Anti-cancer agents in medicinal chemistry·Jul 10, 2026
Reversible and irreversible BTK inhibition promotes stem-like functional multipotency, persistence, and antitumor efficacy of CD19-directed CAR T cells in mantle cell lymphoma.
Yixin Yao, Yue Fei, Fangfang Yan et al.·Leukemia·Jul 9, 2026
Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee.
Peter Dreger, Gloria Iacoboni, Stephen Robinson et al.·Bone marrow transplantation·Jul 9, 2026
Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology.
Jonas Lippl, Sarah Reinke, Karoline Koch et al.·Leukemia·Jul 7, 2026
Stereoselective Covalent Targeting of BTK(C481S) and Kinases with β-Lactone Electrophiles.
Celine D Wang, Polina E Barzova, Julian Robles et al.·bioRxiv : the preprint server for biology·Jul 6, 2026
Ethacrynic Oxadiazole 6u Induces Apoptosis by Targeting mTOR/c-Flip Axis and Noxa in Lymphoma Cells.
Yafei Kuang, Shuoyan Feng, Jinxiao Sun et al.·Biological procedures online·Jul 3, 2026
BRG1-mediated suppression of ferroptosis underlies BTK inhibitor resistance.
Soo-Yeon Hwang, Xiangao Huang, Helgi Nikolli et al.·Nature communications·Jul 2, 2026
Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

Palliative total kidney irradiation for acute kidney injury caused by bilateral renal infiltration of chemotherapy-resistant mantle cell lymphoma: a case report.
Yuki Mochizuki, Hiroyuki Inoo, Tomoaki Yano et al.·International cancer conference journal·Jul 1, 2026
First-line ibrutinib plus venetoclax for non-blastoid mantle cell lymphoma in patients ≥65 years or with TP53 mutations.
Michael Wang, Marc S Hoffmann, Tomasz Wróbel et al.·Blood·Jul 1, 2026
Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.
Toby A Eyre, Yuqin Song, Olivier Hermine et al.·Journal of clinical oncology : official journal of the American Society of Clinical Oncology·Jul 1, 2026
Concurrent Mantle Cell Lymphoma and Paraneoplastic Membranous Nephropathy.
Daoyuan Lv, Ping Sun, Yuanyuan Li et al.·Kidney medicine·Jul 1, 2026
Real Egyptian Single-Center Experience in Mantle Cell Lymphoma Diagnosis and Management.
Esraa Jamal, Doaa H Sakr, Yasmine Shaaban·Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion·Jul 1, 2026
Page 1 of 29Next →